5-Amino-1MQ: NNMT Inhibitor for Fat Loss (Not a Peptide)

5-Amino-1MQ, short for 5-amino-1-methylquinolinium, is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). It is studied as a tool for shifting fat-cell metabolism toward fat burning, and it has built a following in biohacker and fitness circles, including a notable surge of interest on social platforms.

The compound came out of structure-activity relationship work at the University of Texas at Austin, with Neelakantan and colleagues publishing the defining study in the Journal of Medicinal Chemistry in 2017. Its design solved a specific problem: earlier NNMT inhibitors blocked the enzyme well in a test tube but could not cross cell membranes efficiently, making them useless inside living fat cells. 5-Amino-1MQ crosses membranes readily, which is exactly why it became the standard research probe for studying NNMT.

The bottom line: 5-Amino-1MQ is a membrane-permeable small molecule and a research-grade NNMT inhibitor, not a peptide therapy.

5-Amino-1MQ works by blocking NNMT, an enzyme that becomes overactive in obese fat tissue and quietly drains the cell’s metabolic resources. To understand why that matters, you have to follow what NNMT does when it runs unchecked.

NNMT transfers a methyl group from S-adenosylmethionine (SAM), the cell’s main methyl donor, onto nicotinamide. This does two things at once. It consumes SAM, the same molecule the cell needs to methylate DNA and other targets, and it diverts nicotinamide away from the pathway that recycles it into NAD+, a cofactor central to energy metabolism. When NNMT is hyperactive, as it is in obese adipose tissue, SAM gets depleted and NAD+ production suffers.

By inhibiting NNMT, 5-Amino-1MQ is proposed to keep SAM and nicotinamide in play, raise cellular NAD+, support the activity of sirtuins such as SIRT1, and tilt fat cells toward energy expenditure and away from fat storage. In short, it is a metabolic rewiring strategy rather than an appetite suppressant. That is a meaningfully different mechanism from the growth hormone fragments marketed for fat loss, such as AOD-9604, and from the GLP-1 medicines that work largely by reducing appetite.

The bottom line: 5-Amino-1MQ targets a genuine metabolic checkpoint by preserving SAM and NAD+, but a coherent mechanism is not the same as a proven human benefit.

To date there are no published human clinical trials of 5-Amino-1MQ. The entire evidence base consists of cell-culture and animal studies, which is the most important context for anyone weighing the marketing claims.

Metabolic and obesity studies

In diet-induced obese mice, 5-Amino-1MQ treatment significantly reduced body weight, white adipose tissue mass, and the size of individual fat cells, and improved glucose tolerance. Crucially, the researchers reported no significant effect on food intake and no observable adverse effects in those animals, supporting the idea that the weight loss came from a metabolic shift rather than reduced eating. In cultured fat cells, the inhibitor was typically applied at a concentration around 30 micromolar to demonstrate its effect on SAM and NAD+ balance. These findings are why NNMT inhibition is taken seriously as a metabolic-disease target.

Muscle and aging research

NNMT becomes more active in skeletal muscle with age, and inhibiting it has drawn interest as a way to support muscle repair. In aged mice, NNMT inhibitors including 5-Amino-1MQ improved the function of muscle stem cells and increased mitochondrial respiration in older muscle tissue, leading researchers to describe this class as a candidate approach for age-related muscle decline. This work remains entirely preclinical.

Cancer research

Because NNMT is overexpressed in several aggressive cancers, 5-Amino-1MQ has also been tested in laboratory cell lines for osteosarcoma (U-2 OS and Saos-2) and Merkel cell carcinoma (MCC13 and MCC26), where NNMT inhibition reduced cancer-cell viability and proliferation. This is early cell work, far upstream of any clinical application, but it shows NNMT is a broad biological target rather than a fat-loss curiosity.

Research area	Finding	Evidence tier
Obesity / metabolism	Reduced weight and fat mass in obese mice; no change in food intake	Animal
Muscle / aging	Improved muscle stem-cell function in aged mice	Animal
Cancer	Reduced viability in osteosarcoma and Merkel-cell lines	In vitro (cell)
Human use	No published clinical trials	None

The bottom line: 5-Amino-1MQ has encouraging animal data across metabolism, muscle, and cancer research, but no published human evidence to confirm any of it.

5-Amino-1MQ is not approved for human use anywhere and is sold only as research-use-only material. Because it is a small molecule rather than a peptide, it sits outside the peptide-specific compounding rules entirely.

Jurisdiction	Status
United States	Not FDA-approved and not on the 503A Bulks List. As a small molecule it was never part of the peptide Category 2 framework.
United Kingdom	No marketing authorisation; as a small molecule it falls outside the peptide-specific rules; supplied research-use-only.
Australia	Not an approved therapeutic good; supplied as a research chemical, not a scheduled prescription medicine.
WADA (sport)	Not specifically named, but as an unapproved substance it falls under the S0 catch-all, prohibited at all times.

In the United States, the headline peptide reclassification story does not apply to 5-Amino-1MQ. The Category 2 list and the advisory-committee reviews all concern peptide bulk drug substances; a quinolinium small molecule is a different regulatory category, with no legitimate compounding or clinical-access pathway in US practice. For how the peptide system is structured, our guide to the FDA category framework gives the background, with further context in our overview of peptide legality in the US. The position abroad is detailed in our guides to the UK legal stance and peptide legality in Australia.

The bottom line: 5-Amino-1MQ has no approved use anywhere and is available only as an unregulated research chemical.

Because no human trials have been published, the human safety profile of 5-Amino-1MQ is unknown. Animal studies have not flagged prominent adverse effects, but that is a low bar that says nothing about safety in people over time.

There is also a mechanistic reason for caution that does not apply to most fat-loss products. SAM, the molecule 5-Amino-1MQ helps preserve, is the body’s universal methyl donor, used to methylate DNA, histones, and many other targets. Manipulating an enzyme that sits at the centre of methylation balance could plausibly have effects well beyond fat cells, and those effects have not been characterised in humans. That whole-body methylation question is the specific, unresolved concern most unique to this compound. On top of it is the usual research-chemical reality: 5-Amino-1MQ is sold without pharmaceutical oversight, so purity and identity are not guaranteed. Demanding a product’s certificate of analysis and scrutinising the seller’s credibility are the bare minimum checks for anything bought this way.

The bottom line: 5-Amino-1MQ’s human safety is entirely unestablished, and its mechanism touches a fundamental cellular process that has not been studied in people.

Is 5-Amino-1MQ actually a peptide?

No. It is a small molecule of about 159 grams per mole from the quinolinium family, usually supplied as an iodide salt. It is sold alongside peptides because of its metabolic angle, but chemically it has nothing to do with the amino-acid chains that define peptides.

How is it different from a GLP-1 like semaglutide?

Almost entirely. GLP-1 medicines drive weight loss largely by reducing appetite and have large human trials behind them. 5-Amino-1MQ works on intracellular metabolism through NNMT, did not change food intake in animals, and has no human trials at all.

Does it raise NAD+ like NMN or NR?

It approaches NAD+ from a different angle. NMN and NR supply raw material to build NAD+, whereas 5-Amino-1MQ blocks an enzyme that wastes the nicotinamide and SAM needed for NAD+ production. The downstream goal of higher NAD+ overlaps, but the mechanism is the reverse.

Is 5-Amino-1MQ part of the FDA peptide reclassification?

No. The Category 2 list and the advisory-committee reviews apply to peptide bulk drug substances. Being a small molecule, 5-Amino-1MQ was never on that list and is not part of any peptide reclassification process.

The growth hormone fragments AOD-9604 and HGH Fragment 176-191 are marketed for fat loss too, with a different mechanism and, in AOD-9604’s case, a record of failed human trials. The approved GLP-1 medicines semaglutide and tirzepatide work largely through appetite, the opposite of this compound’s metabolic approach, and they have the large human trials it lacks. Like the non-peptide growth hormone secretagogue MK-677, 5-Amino-1MQ is frequently sold alongside peptides despite not being one, a recurring source of confusion in this market. Our roundup of fat-loss and GLP-1 options places it in the wider context.

NNMT inhibition is a legitimate and active area of metabolic-disease research, and 5-Amino-1MQ remains the best-known chemical probe for it. As of 2026, human clinical activity around NNMT inhibitors is described as emerging but not yet mature, meaning early-stage interest exists but completed efficacy trials do not. The realistic near-term picture is more preclinical work and possibly early human studies of NNMT-targeting drug candidates, while the version circulating in consumer and biohacker channels stays a research chemical with no approval. The science is worth watching; the supplement-style marketing is well ahead of the evidence.

The bottom line: NNMT inhibition is a promising research target, but 5-Amino-1MQ is still a preclinical compound being sold years ahead of the human data.